TSP996-CMap - carcinogenome project: Toxicogenomic signatures after exposure to promethazine


TSA9588-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine


TSA8778-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine


TSA9697-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine


TSF12794-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine 100.8 µM


1 subfactor(s)
TSF12795-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine 33.6 µM


1 subfactor(s)
TSF12796-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine 11.2 µM


1 subfactor(s)
TSF9858-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 40.4 µM


1 subfactor(s)
TSF9859-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 20.2 µM


1 subfactor(s)
TSF9860-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 10.1 µM


1 subfactor(s)
TSF9861-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 5.05 µM


1 subfactor(s)
TSF9862-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 2.52 µM


1 subfactor(s)
TSF9863-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 1.26 µM


1 subfactor(s)
TSF13127-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine 100.8 µM


1 subfactor(s)
TSF13128-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine 33.6 µM


1 subfactor(s)
TSF13129-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine 11.2 µM


1 subfactor(s)
TSS12795-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine 100.8 µM


TSS12796-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine 33.6 µM


TSS12797-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to promethazine 11.2 µM


TSS9859-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 40.4 µM


TSS9860-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 20.2 µM


TSS9861-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 10.1 µM


TSS9862-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 5.05 µM


TSS9863-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 2.52 µM


TSS9864-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to promethazine 1.26 µM


TSS13128-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine 100.8 µM


TSS13129-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine 33.6 µM


TSS13130-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to promethazine 11.2 µM



TSP996 - CMap - carcinogenome project: Toxicogenomic signatures after exposure to promethazine Public


In the chemical selection process, we prioritized chemicals with long-term rodent liver carcinogenicity annotation for inclusion in this experiment. Long-term carcinogenicity annotations were derived from the Carcinogenic Potency Database (CPDB) (Fitzpatrick 2008). Additional chemicals without carcinogenicity annotation were included on the basis of interest to the Superfund Research Program (environmental toxicants), presence in controversial commercial products (included for predictive purposes), and evidence of binding to the aryl hydrocarbon receptor (AhR), as the AhR is an important mediator of xenobiotics, including carcinogens. In total, 330 unique chemicals were used in the analysis, including 128 carcinogens, 168 noncarcinogens, 100 genotoxicants, and 161 nongenotoxicants. (Li et al., 2019)

Experimental design


No experimental design provided

Results


No results provided